Research programme: lyophilised platelet derivatives - Cellphire

Drug Profile

Research programme: lyophilised platelet derivatives - Cellphire

Alternative Names: Autologous platelet derivatives - Cellphire; Lyophilised haemostats - Cellphire; Thromboderm; Thrombosomes

Latest Information Update: 26 Sep 2014

Price : $50

At a glance

  • Originator Cellphire
  • Class Blood products and substitutes; Cell therapies
  • Mechanism of Action Blood coagulation stimulants; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Haemorrhage; Wounds

Most Recent Events

  • 27 Aug 2014 Cellphire's lyophilised platelet derivatives programme is available for licensing as of 27 Aug 2014. http://www.cellphire.com/
  • 21 Aug 2014 Preclinical trials in Wounds in USA (Topical) prior to August 2014
  • 21 Aug 2014 Preclinical trials in Haemorrhage in USA (IV) prior to August 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top